IJCEMR

Article http://dx.doi.org/10.26855/ijcemr.2024.01.017

Research Progress of Interferon in the Treatment of Liver Cancer

TOTAL VIEWS: 544

Lian Xie*, Fangyin Xu, Chenwei Pan

The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

*Corresponding author: Lian Xie

Published: March 11,2024

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor in the world and the fourth leading cause of cancer-related death. It is characterized by high incidence, poor prognosis, and high recurrence rates. Most patients are in an advanced stage when they seek treatment, and the therapeutic effect is not satisfactory. Interferon (IFNs) is a kind of cytokine with anti-virus, inhibition of cell proliferation, and induction of apoptosis, which has the advantages of improving cure rate, safe withdrawal of the drug, achieving sustained non-therapeutic immune response, reducing the incidence of liver cancer and avoiding the occurrence of drug resistance, delaying the progression of disease and improving the quality of life. Recent studies have found that IFNs can prevent the occurrence of viral hepatitis-related liver cancer and the recurrence and metastasis of liver cancer after surgery. Still, at the same time, there are also adverse reactions. This article reviews the mechanism of action, treatment, and adverse reactions of IFNs in liver cancer.

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[2] Dai CM, Jin S, Zhang JZ. Effect of Dahuang Zhechong Pills combined with TACE on VEGF, MMP-2, TGF-β1 and immune function of patients with primary liver cancer (blood stasis and collaterals blocking type) [J]. China J Chin Mater Med, 2021, 46(3): 722-729.

[3] Cheng J, Zhao Q, Zhou Y, Tang L, Sheraz M, Chang J, Guo JT. Interferon Alpha Induces Multiple Cellular Proteins That Coordinately Suppress Hepadnaviral Covalently Closed Circular DNA Transcription. J Virol., 2020 Aug 17; 94(17):e00442-20.

[4] Seeger C. Control of viral transcripts as a concept for future HBV therapies [J]. CurrOpin Virol, 2018, 30: 18-23.

[5] LI Yimin, Yuan Lin, Yang Shengyong, et al. ADAR1 expression pattern and HBV replication inhibition in hepatocellular carcinoma cells induced by interferon [J]. Journal of the Third Military Medical University, 2019, 41(14):1336-1342.

[6] Dubrot J, Du PP, Lane-Reticker SK. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol,  2022 Oct; 23 (10): 1495-1506.

[7] Li Jie, Yan Kun, Yang Yi et al. Interleukin-17 promotes the growth and proliferation of mouse hepatocellular carcinoma cells by antagonizing γ- interferon [J]. Journal of Southern Medical University, 2019, 39(01):1-5.

[8] Lan Y R, Sun P, Duan X G, et al. Regulation of interferon alpha on Tfh cell differentiation in mice [J]. Advances in Veterinary Medicine, 2019, 41(2):18-22. (in Chinese)

[9] Wang M, Fan W H, Li C et al. Research progress of avian interferon in immune response [J]. Chinese Journal of Animal Infectious Diseases, 2019, 30(01):211-218. (in Chinese)

[10] Li M, Zhang L, Lu Y, et al. Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonalpha-2a [J]. Virol Sin, 2021, 36(2): 311-320.

[11] Li Y, He M, Gong R, Wang Z, Lu L, Peng S, Duan Z, Feng Y, Liu Y, Gao B. Forkhead O transcription factor 4 restricts HBV covalently closed circular DNA transcription and HBV replication through genetic downregulation of hepatocyte nuclear factor 4 alpha and epigenetic suppression of covalently closed circular DNA via interacting with promyelocytic leukemia protein. J Virol, 2022 Jul 13; 96(13):e0054622.

[12] Luo H, Hu X, Li Y, Lei D, Tan G, Zeng Y, Qin B. The antiviral activity of tripartite motif protein 38 in hepatitis B virus replica-tion and gene expression and its association with treatment responses during PEG-IFN- α antiviral therapy. Virol, 2023 Feb; 579:84-93.

[13] Choi H S J, van Campenhout M J H, van Vuuren A J, et al. Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection [J]. Clin Gastroenterol Hepatol, 2021, 19(9): 1933-40 e1.

[14] Lin Y J, Sun F F, Zeng Z, et al. Combination and intermittent therapy based on pegylated interferon alfa-2a for chronic hepatitis B with nucleoside (nucleotide) analog-experienced resulting in hepatitis B surface antigen clearance: a case report [J]. Viral Immunol, 2022, 35(1):71-75.

[15] Wang H, Li Yan-Chun, Gao Qiu-Ying, et al. Effect of imatinib combined with recombinant human interferon α-2b on serum MMP-2, SALL4 mRNA and AGP levels in patients with accelerated chronic myeloid leukemia [J]. Chinese Journal of Clinical Oncology, 2019, 16(05):468-473.

[16] Liu Q, Rong G, Li Wei, Hu Jianwei, et al. Effect of Ralidomide combined with interferon-alpha on proliferation of multiple mye-loma U266 cells [J]. Chinese Journal of Chronic Disease Prevention and Control, 2019, 27(02):133-136.

[17] Zhou J, Zhang W F. PEG-IFN- α-2A combined with ADV treatment for hepatitis B with high viral load e antigen positive [J]. Journal of Hebei Medicine, 2019, 27(08):1394-1399.

[18] Zhang C Y. Meta-analysis of efficacy and safety of interferon alpha combined with thymosin α1 in the treatment of chronic hepatitis B [D]. Shihezi University, 2018.

[19] Qi Wenqian, Wang Jiangbin, Zhang Q, et al. Early combination therapy of pegylated interferon and nucleoside (acid) analogues can effectively improve the antiviral efficacy and long-term prognosis of HBV DNA-positive primary liver cancer patients after hepatectomy/ablation [J]. Journal of Clinical Hepatobiliary Diseases, 2019, 36(06):1355.

[20] Zhang C F. A retrospective study of chronic hepatitis B treated with pegylated interferon combined with traditional Chinese medicine for 2 years [D]. Shanghai University of Traditional Chinese Medicine, 2023.

[21] Weng DD, Chen L D, Xu X, et al. Efficacy and safety evaluation of nucleoside (acid) drugs combined with interferon in the treatment of patients with low level of hepatitis B surface antigen [J]. Modern Practical Medicine, 2019, 35(01):112-115.

[22] Hu, B., Yu, M., Ma, X., et al. IFN-alpha Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. Cancer Discovery, 2022, 12, 1718-1741.

[23] Jin J. Effect analysis of Entecavir and interferon sequential therapy for chronic hepatitis B with high viral load [J]. Current Medicine, 2018, 24(26):64- 66. (in Chinese)

[24] Zhu SHS, Dong Yi, Zhang Hongfei, et al. Effect of randomized controlled interferon sequential combined with lamivudine antiviral therapy on immune tolerance in children with chronic hepatitis B [J]. Chinese Journal of Hepatology, 2019, 27(8):604-609.

How to cite this paper

Research Progress of Interferon in the Treatment of Liver Cancer

How to cite this paper: Lian Xie, Fangyin Xu, Chenwei Pan. (2024) Research Progress of Interferon in the Treatment of Liver CancerInternational Journal of Clinical and Experimental Medicine Research8(1), 96-101.

DOI: http://dx.doi.org/10.26855/ijcemr.2024.01.017